About Us

Contact Us

Home About Us Product News Order Career Contact


           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd  


Product Indentification

Name:   VX-950
Synonyms:   Telaprevir
CAS Registry Number:   402957-28-2
Molecular Formula:   C36H53N7O6
Molecular Weight:    679.85
Molecular Structure:   402957-28-2|Telaprevir



                   In stock!


                  Appearance:  white solid









                   For Research Used Only



                   Inquiry (H1NMR,HPLC,LC-MS)



Related products:


        907606-68-2|(3aR,6aS)-1-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrol-2-ium carboxyformate


           926276-18-8|Cyclopenta[c]pyrrole-1-carboxylic acid,2-[(2S)-2-[[(2S)-2-amino-2-cyclohexylacetyl]amino]-3,3-dimethyl-1-oxobutyl]octahydro-,1,1-dimethylethyl ester, (1S,3aR,6aS)-


            944716-73-8|(2S,3S)-3-Amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride






Related protease inhibitors:




            402957-28-2|VX-95 0|Telaprevir          



Related pages:

     Search VX-950 or Telaprevir in google
     Search CAS 402957-28-2    in google
     Search C36H53N7O6 in google



Related News:


Telaprevir (VX-950), marketed as the brand name Incivek, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C virus NS3.4A serine protease.

In a randomized controlled trial of patients in whom standard treatment with peginterferon alfa-2a and ribavirin had failed, repeat treatment with the addition of telaprevir was more likely to have a sustained response than repeat treatment with peginterferon alfa-2a and ribavirin alone.

Telaprevir is the first hepatitis C drug that has demonstrated activity in patients who have failed prior therapy.

On April 28, 2011, the FDA Antiviral Drugs Advisory Committee voted 18-0 to recommend approval telaprevir for people with genotype 1 chronic hepatitis C. The committee reviewed clinical trial data (including findings from the Phase 3 ADVANCE, ILLUMINATE, and REALIZE studies) showing that combining telaprevir with pegylated interferon/ribavirin produced a higher cure rate -- and in less time -- than standard therapy alone. This improvement is most notable for hard-to-treat patients including those with HCV genotype 1, people with liver cirrhosis, and those who did not respond to a prior course of interferon-based therapy. Merck's boceprevir, also a new anti hepatitis C drug, was given a positive recommendation by the same committee, on the previous day.Telaprevir was fully approved for use in the United States in May 2011.



Mechanism from nature:



Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved